• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒感染治疗的新视角:当前临床试验概述。

Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials.

机构信息

Department of Advanced Sciences and Technologies in Medicine, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran; Natural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran.

Department of Pediatrics, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran; Natural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran.

出版信息

Int J Biol Macromol. 2020 Dec 15;165(Pt A):18-43. doi: 10.1016/j.ijbiomac.2020.09.204. Epub 2020 Sep 28.

DOI:10.1016/j.ijbiomac.2020.09.204
PMID:32991900
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7521454/
Abstract

The emergence of the global pandemic caused by the novel SARS-CoV-2 virus has motivated scientists to find a definitive treatment or a vaccine against it in the shortest possible time. Current efforts towards this goal remain fruitless without a full understanding of the behavior of the virus and its adaptor proteins. This review provides an overview of the biological properties, functional mechanisms, and molecular components of SARS-CoV-2, along with investigational therapeutic and preventive approaches for this virus. Since the proteolytic cleavage of the S protein is critical for virus penetration into cells, a set of drugs, such as chloroquine, hydroxychloroquine, camostat mesylate have been tested in clinical trials to suppress this event. In addition to angiotensin-converting enzyme 2, the role of CD147 in the viral entrance has also been proposed. Mepolizumab has shown to be effective in blocking the virus's cellular entrance. Antiviral drugs, such as remdesivir, ritonavir, oseltamivir, darunavir, lopinavir, zanamivir, peramivir, and oseltamivir, have also been tested as treatments for COVID-19. Regarding preventive vaccines, the whole virus, vectors, nucleic acids, and structural subunits have been suggested for vaccine development. Mesenchymal stem cells and natural killer cells could also be used against SARS-CoV-2. All the above-mentioned strategies, as well as the role of nanomedicine for the diagnosis and treatment of SARS-CoV-2 infection, have been discussed in this review.

摘要

新型严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)引发的全球大流行促使科学家们在尽可能短的时间内寻找针对该病毒的明确治疗方法或疫苗。如果不能充分了解病毒及其适配蛋白的行为,目前针对这一目标的努力仍将无果而终。本综述概述了 SARS-CoV-2 的生物学特性、功能机制和分子成分,以及针对该病毒的研究性治疗和预防方法。由于 S 蛋白的蛋白水解切割对于病毒进入细胞至关重要,因此已在临床试验中测试了一组药物,如氯喹、羟氯喹、甲磺酸卡莫司他,以抑制该事件。除了血管紧张素转换酶 2 之外,CD147 在病毒进入中的作用也已被提出。美泊利珠单抗已被证明可有效阻断病毒的细胞进入。抗病毒药物,如瑞德西韦、利托那韦、奥司他韦、达芦那韦、洛匹那韦、扎那米韦、帕拉米韦和奥司他韦,也已被测试用于治疗 COVID-19。关于预防疫苗,已提出使用整个病毒、载体、核酸和结构亚单位来开发疫苗。间充质干细胞和自然杀伤细胞也可用于对抗 SARS-CoV-2。本综述讨论了所有上述策略,以及纳米医学在 SARS-CoV-2 感染的诊断和治疗中的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93a/7521454/d2d5ec10fc12/gr10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93a/7521454/726bfec72719/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93a/7521454/800b8097f488/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93a/7521454/c37df540f898/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93a/7521454/66e5257b4630/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93a/7521454/5c96b7ebf399/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93a/7521454/0391930366bc/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93a/7521454/21cf93e943ad/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93a/7521454/f8542bf0d8f3/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93a/7521454/b1010d6e6cb8/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93a/7521454/d2d5ec10fc12/gr10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93a/7521454/726bfec72719/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93a/7521454/800b8097f488/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93a/7521454/c37df540f898/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93a/7521454/66e5257b4630/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93a/7521454/5c96b7ebf399/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93a/7521454/0391930366bc/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93a/7521454/21cf93e943ad/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93a/7521454/f8542bf0d8f3/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93a/7521454/b1010d6e6cb8/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93a/7521454/d2d5ec10fc12/gr10_lrg.jpg

相似文献

1
Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials.新型冠状病毒感染治疗的新视角:当前临床试验概述。
Int J Biol Macromol. 2020 Dec 15;165(Pt A):18-43. doi: 10.1016/j.ijbiomac.2020.09.204. Epub 2020 Sep 28.
2
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.瑞德西韦、洛匹那韦/利托那韦和氯喹/羟氯喹影响新型 SARS-CoV-2 的抗病毒机制研究进展。
Biomed Pharmacother. 2020 Nov;131:110668. doi: 10.1016/j.biopha.2020.110668. Epub 2020 Aug 24.
3
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.SARS-CoV-2:洛匹那韦/利托那韦、达芦那韦/乌苯美司、羟氯喹、瑞德西韦、法匹拉韦等药物治疗新型冠状病毒的抗病毒治疗的最新报告。
Curr Med Chem. 2020;27(27):4536-4541. doi: 10.2174/0929867327666200416131117.
4
COVID-19: morphology and mechanism of the SARS-CoV-2, global outbreak, medication, vaccines and future of the virus.新型冠状病毒肺炎(COVID-19):SARS-CoV-2 的形态与机制、全球疫情爆发、药物治疗、疫苗及病毒的未来。
Front Biosci (Elite Ed). 2021 Dec 20;13(2):272-290. doi: 10.52586/E884.
5
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.药物治疗 2019 冠状病毒病(COVID-19):综述。
JAMA. 2020 May 12;323(18):1824-1836. doi: 10.1001/jama.2020.6019.
6
Safety and Efficacy of Different Therapeutic Interventions on Prevention and Treatment of COVID-19.不同治疗干预措施对新型冠状病毒肺炎防治的安全性与有效性
J Nepal Health Res Counc. 2020 Sep 7;18(2):151-158. doi: 10.33314/jnhrc.v18i2.2806.
7
Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19.正在进行的COVID-19临床试验中的小分子抗病毒药物
Curr Drug Targets. 2021;22(17):1986-2005. doi: 10.2174/1389450122666210215112150.
8
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.FDA 批准了具有治疗 SARS-CoV-2(COVID-19)潜力的药物。
Drug Resist Updat. 2020 Dec;53:100719. doi: 10.1016/j.drup.2020.100719. Epub 2020 Jul 15.
9
SARS-CoV-2: From the pathogenesis to potential anti-viral treatments.严重急性呼吸综合征冠状病毒2:从发病机制到潜在的抗病毒治疗
Biomed Pharmacother. 2021 May;137:111352. doi: 10.1016/j.biopha.2021.111352. Epub 2021 Feb 2.
10
A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.《COVID-19 指南:由新型冠状病毒 SARS-CoV-2 引起的全球大流行》。
FEBS J. 2020 Sep;287(17):3633-3650. doi: 10.1111/febs.15375. Epub 2020 Jun 16.

引用本文的文献

1
Advancements in the development of antivirals against SARS-Coronavirus.抗SARS冠状病毒抗病毒药物的研发进展。
Front Cell Infect Microbiol. 2025 Jan 23;15:1520811. doi: 10.3389/fcimb.2025.1520811. eCollection 2025.
2
SARS-CoV-2 nucleocapsid protein interaction with YBX1 displays oncolytic properties through PKM mRNA destabilization.SARS-CoV-2 核衣壳蛋白与 YBX1 的相互作用通过 PKM mRNA 失稳显示出溶瘤特性。
Mol Cancer. 2024 Nov 6;23(1):248. doi: 10.1186/s12943-024-02153-1.
3
Mannose-specific plant and microbial lectins as antiviral agents: A review.

本文引用的文献

1
CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells.CD147-刺突蛋白是 SARS-CoV-2 感染宿主细胞的新途径。
Signal Transduct Target Ther. 2020 Dec 4;5(1):283. doi: 10.1038/s41392-020-00426-x.
2
Dexamethasone in severe COVID-19 infection: A case series.地塞米松用于重症新型冠状病毒肺炎感染:病例系列
Respir Med Case Rep. 2020;31:101205. doi: 10.1016/j.rmcr.2020.101205. Epub 2020 Aug 28.
3
Dexamethasone nanomedicines for COVID-19.用于治疗新冠肺炎的地塞米松纳米药物。
甘露糖特异性植物和微生物凝集素作为抗病毒药物:综述。
Glycoconj J. 2024 Feb;41(1):1-33. doi: 10.1007/s10719-023-10142-7. Epub 2024 Jan 20.
4
Infections associated with SARS-CoV-2 exploited via nanoformulated photodynamic therapy.通过纳米配方光动力疗法治疗与严重急性呼吸综合征冠状病毒2相关的感染。
ADMET DMPK. 2023 Jul 1;11(4):513-531. doi: 10.5599/admet.1883. eCollection 2023.
5
The role of SARS-CoV-2-mediated NF-κB activation in COVID-19 patients.严重急性呼吸综合征冠状病毒 2 介导体细胞 NF-κB 激活在 COVID-19 患者中的作用。
Hypertens Res. 2024 Feb;47(2):375-384. doi: 10.1038/s41440-023-01460-2. Epub 2023 Oct 23.
6
Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19.间充质干细胞治疗 COVID-19 的临床试验。
Curr Stem Cell Res Ther. 2024;19(8):1055-1071. doi: 10.2174/011574888X260032230925052240.
7
Recent Advances in Early Diagnosis of Viruses Associated with Gastroenteritis by Biosensors.生物传感器在病毒相关胃肠炎的早期诊断中的最新进展。
Biosensors (Basel). 2022 Jul 8;12(7):499. doi: 10.3390/bios12070499.
8
Severe acute respiratory syndrome coronavirus 2 infection: Role of interleukin-6 and the inflammatory cascade.严重急性呼吸综合征冠状病毒2感染:白细胞介素-6及炎症级联反应的作用
World J Virol. 2022 May 25;11(3):113-128. doi: 10.5501/wjv.v11.i3.113.
9
MicroRNA let-7 and viral infections: focus on mechanisms of action.微小 RNA let-7 与病毒感染:作用机制研究进展。
Cell Mol Biol Lett. 2022 Feb 14;27(1):14. doi: 10.1186/s11658-022-00317-9.
10
Emerging importance of nanotechnology-based approaches to control the COVID-19 pandemic; focus on nanomedicine iterance in diagnosis and treatment of COVID-19 patients.基于纳米技术的方法在控制新冠疫情中的重要性日益凸显;聚焦纳米医学在新冠患者诊断和治疗中的迭代应用。
J Drug Deliv Sci Technol. 2022 Jan;67:102967. doi: 10.1016/j.jddst.2021.102967. Epub 2021 Nov 6.
Nat Nanotechnol. 2020 Aug;15(8):622-624. doi: 10.1038/s41565-020-0752-z.
4
Dexamethasone for COVID-19? Not so fast.地塞米松治疗 COVID-19?先别急。
J Biol Regul Homeost Agents. 2020;34(3):1241-1243. doi: 10.23812/20-EDITORIAL_1-5.
5
Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.针对 SARS-CoV-2 的免疫反应和 COVID-19 中免疫病理变化的机制。
Allergy. 2020 Jul;75(7):1564-1581. doi: 10.1111/all.14364.
6
Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.洛匹那韦/利托那韦联合疗法用于印度有症状的 2019 冠状病毒病患者:限制公共卫生紧急使用的方案。
Indian J Med Res. 2020;151(2 & 3):184-189. doi: 10.4103/ijmr.IJMR_502_20.
7
Nanomaterial-based biosensors for detection of pathogenic virus.用于检测致病病毒的基于纳米材料的生物传感器。
Trends Analyt Chem. 2017 Dec;97:445-457. doi: 10.1016/j.trac.2017.10.005. Epub 2017 Oct 13.
8
Molecular immune pathogenesis and diagnosis of COVID-19.新型冠状病毒肺炎的分子免疫发病机制与诊断
J Pharm Anal. 2020 Apr;10(2):102-108. doi: 10.1016/j.jpha.2020.03.001. Epub 2020 Mar 5.
9
The COVID-19 vaccine development landscape.2019冠状病毒病疫苗的研发情况。
Nat Rev Drug Discov. 2020 May;19(5):305-306. doi: 10.1038/d41573-020-00073-5.
10
Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses.针对新兴致病性人类冠状病毒的亚单位疫苗
Front Microbiol. 2020 Feb 28;11:298. doi: 10.3389/fmicb.2020.00298. eCollection 2020.